Beginning a new medication regimen can be challenging
With the right support and a personalized plan, you can overcome those common obstacles that trip up so many people and achieve lasting success
In the Phase 3 TRIUMPH-1 trial reported May 21, 2026, the 12 mg arm produced mean body-weight reduction of 28.3% at 80 weeks, with extension data reaching 30.3% at 104 weeks [1][2]
The Precision Peptide Genetic Test from PlexusDx ($298) analyzes genetic variants affecting peptide sensitivity and GI response, potentially predicting which patients are more prone to GLP-1 diarrhea and informing personalized management from the start
doi: 10.1016/j.heliyon.2021.e05925 444 HuYMZhouFYuanYXuYC
As group vice president at Lilly, DiMarchi generated rDNA-derived medicines that dramatically advanced the treatment of Type 1 and Type 2 diabetes